A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer

Platinum-resistant Epithelial Ovarian Cancer Clinical Trial

Official title:
A Phase I/II Trial Investigating the Tolerability, Toxicity and Efficacy of Hydroxychloroquine and Itraconazole in Patients With Advanced Platinum-resistant Epithelial Ovarian Cancer (EOC) (HYDRA-1 Study)

Status Completed

Clinical Trial Summary

This is a phase I/II study to find the highest dose of hydroxychloroquine that can be given safely with itraconazole in patients with advanced platinum-resistant epithelial ovarian cancer. The study will also determine the safety, tolerability, and initially determine whether the combination is useful in the treatment of patients with advanced platinum-resistant epithelial ovarian cancer.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Carcinoma, Ovarian Epithelial
Ovarian Neoplasms
Platinum-resistant Epithelial Ovarian Cancer

Clinical Trial Details

NCT number	NCT03081702
Study type	Interventional
Source	University Health Network, Toronto
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	July 25, 2017
Completion date	August 27, 2019

View Details

See also
	Status	Clinical Trial	Phase
	Terminated	`NCT04244552` - A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies	Phase 1
	Terminated	`NCT05243524` - Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer	Phase 2